Novartis Agrees to Acquire Avidity Biosciences
Novartis has entered into an agreement to acquire Avidity Biosciences, Inc., a San Diego-based biopharmaceutical company.
Avidity is focused on a new class of therapeutics enabling RNA delivery to muscle, and is working on Antibody Oligonucleotide Conjugates (AOCs) for serious, genetic neuromuscular diseases.
The acquisition will bring Avidity’s late-stage neuroscience programs into Novartis, providing access to a differentiated RNA-targeting delivery platform, following the separation of Avidity’s early-stage precision cardiology programs.
Author's summary: Novartis acquires Avidity Biosciences to expand its RNA therapeutics portfolio.
More News
- West Indies ease past Bangladesh in first T20I
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- 2 US Navy aircraft crash in South China Sea
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Albion Online’s “Realm Divided” Update Transforms Faction Warfare This November
- The Founding of New York - Historic UK
- Organon CEO stands down amid contraceptive sales malpractice probe - Pharmaceutical Technology
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Global PAH data shows rising cases and risk factors in elderly
- Confronting deepfakes - Opinion News | The Financial Express